Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol-Myers Squibb news coverage encompasses regulatory developments, clinical trial results, product launches, business transactions, and corporate initiatives. The company's activities across oncology, hematology, immunology, cardiovascular, and neuroscience generate frequent updates that impact stakeholders in the healthcare and investment communities.
Regulatory announcements represent significant news events for Bristol-Myers Squibb, including approvals of new medicines, expanded indications for existing products, and regulatory submissions in various markets. These milestones reflect the progression of the company's pipeline from clinical development through regulatory review to market authorization. Priority review designations, breakthrough therapy designations, and orphan drug designations also generate news coverage as indicators of regulatory progress.
Clinical trial data releases occur at medical conferences, in peer-reviewed publications, and through corporate announcements. Results from pivotal trials evaluating new medicines or expanded uses of approved products receive particular attention from the medical community and investors. The company's extensive clinical trial portfolio across multiple therapeutic areas produces a steady stream of data readouts that inform understanding of product profiles and market potential.
Business development activities including acquisitions, licensing agreements, research collaborations, and strategic partnerships shape Bristol-Myers Squibb's long-term direction. These transactions can bring new assets into the pipeline, provide access to novel technologies, or establish collaborations with academic institutions and biotechnology companies. Divestitures and portfolio prioritization decisions also generate news coverage.
Commercial performance updates occur through periodic financial reporting and corporate presentations. These updates provide insight into product uptake, market penetration, competitive dynamics, and the impact of healthcare policy changes on business results. Manufacturing capacity expansions, supply chain developments, and commercial launches in new geographic markets represent additional categories of business news.
Corporate initiatives related to sustainability, patient access, health equity, research funding, and community engagement reflect broader aspects of Bristol-Myers Squibb's operations beyond drug development and commercialization. Leadership changes, organizational restructuring, and strategic priority shifts also contribute to news flow.
Bristol Myers Squibb (NYSE: BMY) will present at J.P. Morgan’s 41st Annual Healthcare Conference on January 9, 2023. The presentation will be led by Giovanni Caforio, M.D., the Board Chair and CEO, at 7:30 a.m. PST / 10:30 a.m. EST. A live webcast will be available at http://investor.bms.com, with additional materials accessible at the start of the event. A replay will follow. Bristol Myers Squibb is dedicated to developing innovative medicines for serious diseases.
Bristol Myers Squibb (NYSE: BMY) has finalized the sale of its manufacturing facility in
Bristol Myers Squibb (NYSE:BMY) will reveal its Q4 2022 financial results on
Bristol Myers Squibb (NYSE: BMY) presented new data from its multiple myeloma portfolio at the 64th ASH Annual Meeting. The results include advancements in bispecific T cell engagers and CAR T therapies, such as alnuctamab, Abecma, and GPRC5D CAR T. Notable findings include alnuctamab showing reduced toxicity with sustained tumor response, while Abecma demonstrated high overall response rates in patients after relapse. The company emphasizes its commitment to innovative treatments in addressing the complex challenges of multiple myeloma.
Bristol Myers Squibb (NYSE: BMY) has declared a quarterly dividend of $0.57 per share, payable on February 1, 2023, to stockholders on record by January 6, 2023. This marks a 5.6% increase from last year’s dividend of $0.54 and continues a strong trend, being the 14th consecutive year of increases and the 91st year of dividend payments overall, which reflects the company's commitment to returning value to its shareholders. An additional dividend of $0.50 per share will be paid on preferred stock on March 1, 2023.
On Nov. 29, 2022, Bristol Myers Squibb (NYSE: BMY) announced a multi-year research collaboration with Envisagenics to leverage the latter's SpliceCore® AI platform for oncology therapeutic development. The partnership aims to enhance BMY's oncology pipeline by identifying alternative splicing-derived targets. Envisagenics will receive upfront and milestone payments tied to development progress. The SpliceCore platform promises rapid drug target identification through advanced RNA-sequencing data analysis, potentially transforming modern drug development.
Bristol Myers Squibb (NYSE: BMY) will participate in a fireside chat at the Wolfe Research Healthcare Conference on
Bristol Myers Squibb (NYSE: BMY) recently presented significant findings from its cardiovascular portfolio at the AHA Scientific Sessions 2022. Key topics included a featured presentation on CAMZYOS® (mavacamten) for obstructive hypertrophic cardiomyopathy, showcasing long-term efficacy and safety data from various studies. Highlights also included analyses of racial disparities in anticoagulant treatment among Medicare beneficiaries and pooled safety data from multiple trials. These presentations underscore the commitment to innovative cardiovascular treatments aimed at improving patient outcomes.
Bristol Myers Squibb (NYSE: BMY) announced that its Phase 3 COMMANDS trial of Reblozyl (luspatercept-aamt) achieved primary and key secondary endpoints, demonstrating significant improvement in red blood cell transfusion independence and hemoglobin levels for patients with very low, low, or intermediate-risk myelodysplastic syndromes (MDS) requiring transfusions. The safety profile remains consistent with previous studies. Detailed findings will be presented at an upcoming medical meeting as the company collaborates with health authorities for further evaluations.
Obsidian Therapeutics has announced the extension of its strategic collaboration with Bristol Myers Squibb (BMY) for the development of novel cell therapies utilizing Obsidian's cytoDRiVE® technology. This partnership, initiated in 2019, allows Bristol Myers Squibb to in-license worldwide rights for these therapies aimed at cancer treatment. Obsidian stands to gain potential milestone and royalty payments. The announcement coincides with the clinical entry of Obsidian's lead program, OBX-115, designed to improve treatment outcomes in patients with solid tumors.
FAQ
What is the current stock price of Bristol-Myers Squibb Co (BMY)?
What is the market cap of Bristol-Myers Squibb Co (BMY)?
